Key Details
Price
$8.86Annual ROE
1.74%Beta
1.22Events Calendar
Next earnings date:
Mar 14, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 14, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at Sidoti Small Cap Conference on December 4, 2024.
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Appoints Ronald Hundzinski to the Board of Directors.
InfuSystem Holdings, Inc. (NYSE:INFU ) Q3 2024 Results Conference Call November 7, 2024 9:00 AM ET Company Participants Joe Dorame - Managing Partner Rich Dilorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Jim Sidoti - Sidoti & Company Brooks O'Neil - Lake Street Capital Markets Kyle Bauser - B. Riley Securities Matt Hewitt - Craig-Hallum Capital Group Aaron Warwick - Breakout Investors Operator Good day, and welcome to the InfuSystem Third Quarter of 2024 Financial Results Conference Call.
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Third Quarter 2024 Financial Results on November 7, 2024.
The medical device market, a powerhouse sector, is projected to exceed $600 billion by 2025. This growth is fueled by a combination of factors, including an aging population, rising healthcare costs, and rapid technological advancements powered by advanced artificial intelligence (AI) and biotechnology.
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate in Lytham Partners Fall 2024 Investor Conference on October 1, 2024.
FORT WORTH, TX, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on improving clinical outcomes and reducing healthcare expenditures in the surgical, chronic wound and skincare markets, and InfuSystem, Inc. (“InfuSystem”), the operational subsidiary of Sanara's joint venture partner InfuSystem Holdings, Inc., announced today the execution of an exclusive United States distribution agreement with, and minority investment in, ChemoMouthpiece, LLC (“ChemoMouthpiece”).
InfuSystem Holdings, Inc. (NYSE:INFU ) Q2 2024 Earnings Call Transcript August 8, 2024 9:00 AM ET Company Participants Joe Dorame - Investor Relations Rich Dilorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Capital Group Jim Sidoti - Sidoti & Company Operator Good day, and welcome to the InfuSystem Holdings, Inc. Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at Sidoti Small Cap Conference on June 12, 2024.
InfuSystem stock has not performed well compared to the S&P 500, but the company has made significant investments that are expected to pay off in 2024 and beyond. The company's struggles over the past two years were due to making investments that will be monetized in 2024 and beyond. INFU's biomed and wound care businesses are expected to drive growth in 2024, with opportunities for expansion and increased profitability.
FAQ
- What is the primary business of InfuSystem Holdings?
- What is the ticker symbol for InfuSystem Holdings?
- Does InfuSystem Holdings pay dividends?
- What sector is InfuSystem Holdings in?
- What industry is InfuSystem Holdings in?
- What country is InfuSystem Holdings based in?
- When did InfuSystem Holdings go public?
- Is InfuSystem Holdings in the S&P 500?
- Is InfuSystem Holdings in the NASDAQ 100?
- Is InfuSystem Holdings in the Dow Jones?
- When was InfuSystem Holdings's last earnings report?
- When does InfuSystem Holdings report earnings?
- Should I buy InfuSystem Holdings stock now?